Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To determine the efficacy of combined continuous sorafenib therapy and drug-eluting bead (DEB) transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Radiology

Title: Radiology

Publisher: Radiological Society of North America (RSNA)

ISSN (Electronic): 1527-1315

ISSN (Print): 0033-8419

Publication date (Electronic): Nov 2015

Volume: 277

Issue: 2

Affiliations

[1 ] From the Departments of Medical Oncology (D.P.C.), Interventional Radiology (D.K.R., A.L.F., J.F.H.G.), Surgical Oncology (T.M.P.), and Radiology (I.R.K.), Johns Hopkins University School of Medicine, 1800 Orleans St, Sheikh Zayed Tower, Suite 7203, Baltimore, MD 21287.

Article

DOI: 10.1148/radiol.2015142481

PubMed ID: 26069923

SO-VID: be49af7e-1c1d-4f59-95df-218c73927eae

History

Data availability:

Comments

Comment on this article

scite_

Cited by 15

See all cited by